시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 세균성 결막염 시장 보고서(2025년)
Bacterial Conjunctivitis Global Market Report 2025
상품코드 : 1824594
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 세균성 결막염 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년까지 CAGR 3.5%로 확대되어 54억 2,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 세계 인구 증가, 도시화와 오염 증가, 예방 안과 의료에 대한 주목이 높아지고, 세계적인 건강에 대한 대비 노력, 원격 안과 서비스의 확대, 연구 개발에 있어서의 협력에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 약물 전달 기술의 혁신, 치료 요법의 맞춤화, 광역 항생제 사용, 보조 요법의 도입, 환자 교육 및 예방 전략의 중요성 등이 있습니다.

향후 5년간의 성장률 3.5%라는 예측은 이 시장에 관한 지난 예측으로부터 0.3%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역마찰은 스페인과 영국에서 개발된 플루오로퀴놀론계 점안약과 안구 배양 배지의 가격을 상승시켜 홍안병의 유행이 장기화되고 긴급 안과 의료비가 증가하여 미국의 안과의료에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

세균성 결막염 시장은 눈 감염의 유병률이 증가함에 따라 성장할 것으로 예측됩니다. 박테리아, 바이러스, 곰팡이, 기생충과 같은 미생물에 의해 유발된 안구 감염은 결막염, 트라코마, 각막염 등의 질환을 포함합니다. 세균성 결막염의 제형화된 약물 및 위생 조치로 치료할 수 있는 특정 유형은 증가하는 경향이 있습니다. 예를 들어, 2021년 세계보건기구(WHO)는 약 6만 9,000명이 눈의 세균 감염인 트라코마의 후기 단계에서 수술을 받았고, 6,460만명이 트라코마 항생제 치료를 받았다고 보고했습니다. 게다가 BrightFocus Foundation은 세계 녹내장 환자가 2022년 8천만 명에 달했고, 2040년 1억 1100만 명 가까이 증가할 것으로 예측했습니다. 따라서 눈 감염증의 유병률 증가가 세균성 결막염 시장의 성장의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Bacterial conjunctivitis is an infection affecting the mucous membrane of the eye, known as the conjunctiva. This membrane extends from the back surface of the eyelids (palpebral and tarsal conjunctiva) to the fornices and over the globe (bulbar conjunctiva) until it merges with the cornea at the limbus. This condition is highly contagious, easily transmitted through direct or indirect contact with the infected person's eye secretions.

The primary types of bacterial conjunctivitis include hyperacute bacterial conjunctivitis, acute bacterial conjunctivitis, and chronic bacterial conjunctivitis. Hyperacute bacterial conjunctivitis is an exceptionally severe and rapidly progressing form of this infection, characterized by inflammation of the conjunctiva. Various drug classes, such as antibiotics, fluoroquinolones, aminoglycosides, macrolides, antihistamines, corticosteroids, and others, are available for treatment. These medications can be administered through different routes, including oral and topical. Distribution channels for these drugs encompass hospital pharmacies, retail pharmacies, online pharmacies, and other outlets.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The bacterial conjunctivitis market research report is one of a series of new reports from The Business Research Company that provides bacterial conjunctivitis market statistics, including bacterial conjunctivitis industry global market size, regional shares, competitors with a bacterial conjunctivitis market share, detailed bacterial conjunctivitis market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial conjunctivitis industry. This bacterial conjunctivitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bacterial conjunctivitis market size has grown steadily in recent years. It will grow from $4.52 billion in 2024 to $4.72 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to increasing incidence of bacterial infections, improved diagnostic capabilities, patient education and awareness programs, stringent regulatory framework, physician training and expertise.

The bacterial conjunctivitis market size is expected to see steady growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to global population growth, rising urbanization and pollution, increased focus on preventive eye care, global health preparedness initiatives, expansion of teleophthalmology services, collaboration in research and development. Major trends in the forecast period include innovation in drug delivery technologies, customization of treatment regimens, utilization of broad-spectrum antibiotics, introduction of adjunctive therapies, emphasis on patient education and prevention strategies.

The forecast of 3.5% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. ophthalmology care by inflating prices of fluoroquinolone eye drops and ocular culture media developed in Spain and the UK, resulting in prolonged pink eye outbreaks and higher urgent eye care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The bacterial conjunctivitis market is poised for growth due to the increasing prevalence of eye infections. Eye infections, caused by microorganisms such as bacteria, viruses, fungi, or parasites, encompass conditions such as conjunctivitis, trachoma, and keratitis. Bacterial conjunctivitis, a specific type treatable with prescribed medications and hygiene measures, is on the rise. For instance, in 2021, the World Health Organization reported that approximately 69,000 people underwent surgery for the late stage of trachoma, an eye bacterial infection, while 64.6 million received antibiotics treatment for trachoma. Additionally, The BrightFocus Foundation noted that the global glaucoma sufferers reached 80 million in 2022, projected to rise to nearly 111 million by 2040. Hence, the increasing prevalence of eye infections is a driving force behind the growth of the bacterial conjunctivitis market.

The bacterial conjunctivitis market is expected to experience growth fueled by the increasing geriatric population. Individuals aged 65 and older are more susceptible to bacterial conjunctivitis due to age-related changes in the immune system and a higher likelihood of comorbidities. The World Health Organization's report in October 2022 projected that by 2030, 1 in 6 people globally would be aged 60 or above, reaching 1.4 billion. Furthermore, by 2050, the population aged 60 and older is expected to double to 2.1 billion, with those 80 and older tripling to 426 million. This demographic shift toward an aging population is a key factor driving the bacterial conjunctivitis market.

Major players in the bacterial conjunctivitis market are intensifying their efforts to develop innovative eye drops, particularly broad-spectrum eye drops, to optimize their revenues. These medications are specifically formulated to address various eye infections caused by diverse bacteria. Unsuch as targeting specific bacterial types, broad-spectrum eye drops contain antibiotics effective against a wide range of bacteria. An example of this is the launch of Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% by Harrow Health, a US-based pharmaceutical company, in June 2023. Vigamox, a fluoroquinolone antibiotic eye drop, is designed for the treatment of bacterial conjunctivitis.

In January 2023, Harrow Health further strengthened its position in the ophthalmic pharmaceutical market by acquiring the U.S. commercial rights to five ophthalmic drugs, namely Ilevro, Nevanac, Vigamox, Maxidex, and Triesence, from Novartis AG for $175 million. This strategic acquisition is expected to support Harrow Health's expansion in the field of ophthalmology, serving as a valuable addition to its geographic reach. Novartis AG, a Swiss-based pharmaceutical company, specializes in offering a diverse range of medications tailored to treat various eye conditions, including bacterial conjunctivitis.

Major companies operating in the bacterial conjunctivitis market report are Pfizer Inc., Johnson & Johnson, F. Hoffman La-Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Alcon, Sun Pharmaceutical Industries Ltd., Bausch + Lomb, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Hikma Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Alembic Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Ocular Therapeutix Inc., Aldeyra Therapeutics, Nicox SA, IACTA Pharmaceuticals Inc., Cellics Therapeutics Inc.

North America was the largest region in the bacterial conjunctivitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bacterial conjunctivitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bacterial conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bacterial conjunctivitis market consists of revenues earned by entities by providing services such as diagnostic tests, visual acuity testing, and physical examinations. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial conjunctivitis market also includes sales of eye drops, eye ointments, cold compresses, and artificial tears. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bacterial Conjunctivitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bacterial conjunctivitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bacterial conjunctivitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bacterial conjunctivitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Bacterial Conjunctivitis Market Characteristics

3. Bacterial Conjunctivitis Market Trends And Strategies

4. Bacterial Conjunctivitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bacterial Conjunctivitis Growth Analysis And Strategic Analysis Framework

6. Bacterial Conjunctivitis Market Segmentation

7. Bacterial Conjunctivitis Market Regional And Country Analysis

8. Asia-Pacific Bacterial Conjunctivitis Market

9. China Bacterial Conjunctivitis Market

10. India Bacterial Conjunctivitis Market

11. Japan Bacterial Conjunctivitis Market

12. Australia Bacterial Conjunctivitis Market

13. Indonesia Bacterial Conjunctivitis Market

14. South Korea Bacterial Conjunctivitis Market

15. Western Europe Bacterial Conjunctivitis Market

16. UK Bacterial Conjunctivitis Market

17. Germany Bacterial Conjunctivitis Market

18. France Bacterial Conjunctivitis Market

19. Italy Bacterial Conjunctivitis Market

20. Spain Bacterial Conjunctivitis Market

21. Eastern Europe Bacterial Conjunctivitis Market

22. Russia Bacterial Conjunctivitis Market

23. North America Bacterial Conjunctivitis Market

24. USA Bacterial Conjunctivitis Market

25. Canada Bacterial Conjunctivitis Market

26. South America Bacterial Conjunctivitis Market

27. Brazil Bacterial Conjunctivitis Market

28. Middle East Bacterial Conjunctivitis Market

29. Africa Bacterial Conjunctivitis Market

30. Bacterial Conjunctivitis Market Competitive Landscape And Company Profiles

31. Bacterial Conjunctivitis Market Other Major And Innovative Companies

32. Global Bacterial Conjunctivitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bacterial Conjunctivitis Market

34. Recent Developments In The Bacterial Conjunctivitis Market

35. Bacterial Conjunctivitis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기